Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF

NCT02946554 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute-On-Chronic Liver Failure

Interventions

BIOLOGICAL: HepaStem

Sponsor

Cellaion SA